TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23391421
Drug: G-CSF (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (10 μg/kg)
Study: 17699350
Drug: Intravenous C.E.R.A.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous C.E.R.A. 0.4 microg/kg
Study: 17699350
Drug: Subcutaneous C.E.R.A.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous C.E.R.A. 0.8 microg/kg
Study: 10757572
Drug: Control (continued
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (continued catecholamine therapy without milrinone)
Study: 7587035
Drug: Cefotaxime 2
Normalized name: cefotaxime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime 2 g every 12 h
Study: 24458836
Drug: Family-based behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-based behavioral weight loss treatment (FBT) program, 16 sessions
Study: 19900797
Drug: Therapeutic interventions
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic interventions (excluding combination products)
Study: 16881772
Drug: Intensive behavior
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive behavior therapy
Study: 17667481
Drug: Prescribed medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescribed medication
Study: 12360153
Drug: Avasimibe at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avasimibe at 50 mg daily
Study: 12360153
Drug: Avasimibe at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avasimibe at 250 mg daily
Study: 12360153
Drug: Avasimibe at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avasimibe at 750 mg daily
Study: 12360153
Drug: Background lipid-lowering
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Background lipid-lowering therapy
Study: 6794587
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg desmethyl‐diazepam
Study: 30573355
Drug: Drink rich
Normalized name: Maltose-rich malted barley extract
DrugBank: Barley malt syrup (DB14601)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drink rich in polyphenols from red grape pomace (RGPD) - 1.562 g gallic acid equivalents (GAE)
Study: 27776459
Drug: Plant sterols-enriched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant sterols-enriched soy milk (2.0 g free plant sterols daily)
Study: 17245799
Drug: Weekly, monthly,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly, monthly, or occasional religious participation
Study: 11309552
Drug: Nebivolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol (5 mg once a day)
Study: 2837300
Drug: Enalapril 5
Normalized name: enalapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 5 mg twice each week
Study: 12846491
Drug: Tamoxifen (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (administered for at least 3 years)
Study: 2665661
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose trimethoprim
Study: 23280432
Drug: SIT group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIT group (specific immunotherapy)
Study: 10582197
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium 4 mg b.i.d. (two times daily)
Study: 10582197
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium 4 mg q.i.d. (four times daily)
Study: 7788003
Drug: Propylthiouracil treatment
Normalized name: Propylthiouracil
DrugBank: Propylthiouracil (DB00550)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propylthiouracil treatment
Study: 2195937
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (budesonide 200 micrograms twice a day)
Study: 2195937
Drug: Inhaled bronchodilators
Normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled bronchodilators (terbutaline 250 micrograms, two puffs four times a day)
Study: 2195937
Drug: Inhaled bronchodilators
Normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled bronchodilators (Group A)
Study: 2195937
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (Group B)
Study: 29118299
Drug: Triple antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple antiplatelet therapy (TAT; aspirin, clopidogrel, and cilostazol)
Study: 24817596
Drug: Glucose solution
Normalized name: TrueControl Glucose Solution Level 0
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucose solution (reference food)
Study: 22569355
Drug: Piperacillin population
Normalized name: Piperacillin
DrugBank: Piperacillin (DB00319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Piperacillin population pharmacokinetics
Study: 11952478
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) using verteporfin
Study: 11952478
Drug: Anti-vascular endothelial
Normalized name: endothelial growth factor A, vascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-vascular endothelial growth factor (VEGF) agents
Study: 7614522
Drug: Loracarbef 200
Normalized name: loracarbef 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loracarbef 200 mg BID
Study: 7614522
Drug: Loracarbef 400
Normalized name: loracarbef 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loracarbef 400 mg BID
Study: 2645756
Drug: Benazepril 40
Normalized name: benazepril 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril 40 mg once daily
Study: 2645756
Drug: Benazepril 80
Normalized name: Bénazépril
DrugBank: Benazepril (DB00542)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benazepril 80 mg once daily
Study: 495045
Drug: hypertonic glycerol
Approvals — FDA: no, EMA: no, PMDA: no
Description: hypertonic glycerol infusion plus dexamethasone
Study: 26103528
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g intravenous cefazolin
Study: 26103528
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g intravenous cefazolin
Study: 26103528
Drug: Both 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both 2 g and 3 g intravenous cefazolin
Study: 21875678
Drug: Sinovial(®) (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinovial(®) (16 mg/2 ml, 0.8% highly purified intra-articular hyaluronic acid)
Study: 21875678
Drug: Synvisc(®) (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synvisc(®) (16 mg/2 ml, 0.8% hylan G-F20)
Study: 17388716
Drug: Cyproterone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone (100 mg/day)
Study: 17388716
Drug: Haloperidol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (2 mg/day)
Study: 17201083
Drug: Heparin-concentration-based system
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-concentration-based system (HMS)
Study: 10368245
Drug: 15 mL
Normalized name: ethanol 0.15 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mL of 2% lidocaine gel administered intrarectally 15 min before biopsies (group 1)
Study: 10368245
Drug: 15 mL
Normalized name: ethanol 0.15 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mL of trans-sonic hydrophilic gel administered transrectally (placebo, group 2)
Study: 8683250
Drug: Oral cladribine
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral cladribine 10 mg/m2/d for 5 consecutive days in monthly courses
Study: 1913759
Drug: Glyceryl trinitrate
Normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glyceryl trinitrate (0.3 mg sublingual)
Study: 1913759
Drug: Indomethacin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (100 mg orally)
Study: 1913759
Drug: Ibuprofen (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (800 mg orally)
Study: 6814225
Drug: Verapamil, 480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil, 480 mg daily
Study: 30643924
Drug: 200 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg glucagon after 45 min of cycling
Study: 30643924
Drug: 200 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg glucagon before cycling
Study: 26377322
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy (A)
Study: 26377322
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy (B)
Study: 26377322
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy plus massage therapy (C)
Study: 15208206
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy based on estrogen receptor content
Study: 16200721
Drug: Soybean lecithin
Normalized name: soybean lecithin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soybean lecithin 10 g tid
Study: 16200721
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (Basic treatment group)
Study: 9635386
Drug: premixed insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: premixed insulin administered by pen
Study: 7944878
Drug: m-Chlorophenylpiperazine (MCPP)
Normalized name: m-phenylenediamine
DrugBank: m-Chlorophenylpiperazine (DB12110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: m-Chlorophenylpiperazine (MCPP) 0.1 mg/kg
Study: 7944878
Drug: yohimbine hydrochloride
Normalized name: Yohimbine Hydrochloride
DrugBank: Yohimbine (DB01392)
Approvals — FDA: no, EMA: no, PMDA: no
Description: yohimbine hydrochloride 0.4 mg/kg
Study: 25468636
Drug: Double low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double low protocol (iodixanol at 270 mg iodine/ml, 100 kVp tube voltage, AIDR)
Study: 25468636
Drug: Conventional protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional protocol (iopamidol at 370 mg iodine/ml, 120 kVp tube voltage, FBP)
Study: 8751023
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments including grapefruit juice
Study: 8751023
Drug: Treatments including
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatments including grapefruit juice
Study: 2236369
Drug: Cognitive‐behavioural therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐behavioural therapy (average number of sessions: 7.2)
Study: 30335626
Drug: Pregabalin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (150 mg twice daily, n = 40)
Study: 25457902
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg macitentan
Study: 25457902
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg macitentan
Study: 21854292
Drug: Smoking cessation
Normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking cessation treatment (group counseling weeks 1-8 + transdermal nicotine patch 21 mg/day weeks 1-6; 14 mg/day weeks 7-8)
Study: 21854292
Drug: Substance abuse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substance abuse treatment as usual
Study: 17596218
Drug: ketamine-propofol admixture
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ketamine-propofol admixture (0.5 mg/ml ketamine in 10 mg/ml propofol)
Study: 17596218
Drug: lidocaine-propofol admixture
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lidocaine-propofol admixture (1 mg/ml lidocaine in 10 mg/ml propofol)
Study: 15294063
Drug: Pulmicort Turbuhaler
Normalized name: Pulmicort Turbuhaler
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pulmicort Turbuhaler (budesonide inhalation powder) two puffs (400 microg) bid
Study: 15294063
Drug: pressurized metered-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: pressurized metered-dose inhalers (pMDIs)
Study: 9169397
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin treatment (insulin-glucose infusion for at least 24 hours followed by multidose insulin treatment)
Study: 9169397
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin treatment (in predefined group without previous insulin treatment and low cardiovascular risk)
Study: 9169397
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (control group in predefined group without previous insulin treatment and low cardiovascular risk)
Study: 28361971
Drug: PG2 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: PG2 (500 mg, IV) administered 3 doses per week for 2 weeks
Study: 23433461
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy for 48 months (clopidogrel plus aspirin)
Study: 23433461
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy for 12 months (clopidogrel plus aspirin)
Study: 12577352
Drug: Chemotherapy combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy combined with Guben Yiliu III (GBYL)
Study: 12577352
Drug: Chemotherapy combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy combined with moxibustion and Guben Yiliu III (GBYL)
Study: 2427836
Drug: Propranolol 40
Normalized name: propranolol 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 40 mg (pretreatment)
Study: 25187399
Drug: Bapineuzumab (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bapineuzumab (6 doses intravenously once every 13 weeks)
Study: 18353720
Drug: Carperitide infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carperitide infusion (group II)
Study: 10869261
Drug: Cariporide (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cariporide (40 mg intravenous bolus)
Study: 9374084
Drug: Paclitaxel 200
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 200 mg/m2 intravenously over 3 hours for eight cycles over 24 weeks
Study: 9374084
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with oral cyclophosphamide 100 mg/m2/d days 1 to 14, intravenous methotrexate 40 mg/m2 days 1 and 8, intravenous 5‐fluorouracil 600 mg/m2 days 1 and 8, and oral prednisone 40 mg/m2 daily days 1 to 14 (CMFP) for six cycles over 24 weeks
Study: 1546547
Drug: Clomipramine (25‐75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine (25‐75 mg; flexible dosage)
Study: 27881106
Drug: Multifamily therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multifamily therapy (MFT-AN)
Study: 27881106
Drug: Single family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single family therapy (FT-AN)
Study: 22709755
Drug: Ranolazine (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranolazine (1,000 mg twice daily for 7 days)
Study: 18280116
Drug: 100mg immediate-release
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg immediate-release (IR) tablets
Study: 18280116
Drug: 250mg controlled-release
Normalized name: Slo-Niacin 250mg Controlled-Release Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250mg controlled-release (CR) tablets
Study: 15699835
Drug: Cessation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cessation of enteral tube feeding for RV >400 mL in study patients
Study: 15699835
Drug: Cessation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cessation of enteral tube feeding for RV >200 mL in controls
Study: 15699835
Drug: RV <150
Approvals — FDA: no, EMA: no, PMDA: no
Description: RV <150 mL
Study: 15699835
Drug: RV >400
Approvals — FDA: no, EMA: no, PMDA: no
Description: RV >400 mL
Study: 15699835
Drug: RV >300
Approvals — FDA: no, EMA: no, PMDA: no
Description: RV >300 mL
Study: 15699835
Drug: RV >200
Approvals — FDA: no, EMA: no, PMDA: no
Description: RV >200 mL
Study: 15699835
Drug: RV >150
Approvals — FDA: no, EMA: no, PMDA: no
Description: RV >150 mL
Study: 12426766
Drug: Novel drug
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel drug delivery system with average particle size between 1-150 microns
Study: 7814484
Drug: Monovalent influenza
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent influenza A/Taiwan/1/86 (H1N1) virus HA, doses ranging from 0 to 405 micrograms per dose
Study: 7814484
Drug: Trivalent HA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent HA vaccine containing A/H1N1, A/H3N2, and influenza B virus HA, doses ranging from 0 to 135 micrograms per strain, 0 to 405 micrograms per dose
Study: 7814484
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of commercial influenza vaccine (control group)
Study: 2528230
Drug: Alternative group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative group with 1/5 of the treatment group's exercise program per session
Study: 17803844
Drug: Paroxetine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine + Zolpidem (Group A, treated with paroxetine 10 ‐ 20 mg/d and zolpidem 10 mg/d for 4 weeks)
Study: 12139731
Drug: Increased intensity
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Increased intensity of therapy
Study: 8074012
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of cold air (−22 degrees C) during exercise
Study: 8074012
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of thermoneutral air (22 degrees C) during exercise
Study: 766497
Drug: Target therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target therapy as per antibiogram
Study: 766497
Drug: Blind early
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blind early therapy with Nifurantin
Study: 23816952
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of CO2 (all concentrations)
Study: 17005526
Drug: pH neutral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: pH neutral, lactate-buffered, low GDP solution (balance)
Study: 15021447
Drug: Raloxifene (RAL)
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Raloxifene (RAL) 60 mg/day
Study: 11710752
Drug: Intravenous hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous hydrocortisone (0, 25, 50, 100 or 200 mg)
Study: 2036070
Drug: Madopar HBS
Normalized name: HBSAG
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Madopar HBS (sustained-release preparation)
Study: 2036070
Drug: Madopar M
Normalized name: Coenzyme M
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Madopar M (standard preparation)
Study: 27515070
Drug: Ustekinumab (Arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab (Arm 1: immediate cessation of methotrexate; Arm 2: 4 weeks' overlap with decreasing methotrexate dose)
Study: 24916903
Drug: Lipocalin-2 treatment
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lipocalin-2 treatment in microglia
Study: 24916903
Drug: Lipocalin-2 treatment
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lipocalin-2 treatment in astrocytes
Study: 18409186
Drug: Suspicious Digital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspicious Digital Rectal Examination (DRE)
Study: 10617237
Drug: Low-dose dopamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dopamine (LDD) at doses of 0-5 microg/kg/min
Study: 10617237
Drug: Low-dose dopamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dopamine (LDD)
Study: 1425818
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (bromocriptine + levodopa) for 5 years
Study: 1425818
Drug: Levodopa alone
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa alone therapy for 5 years
Study: 1425818
Drug: Maintained combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintained combination therapy for 5 years
Study: 4065703
Drug: Scheduled intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scheduled intramuscular morphine injections
Study: 29128486
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose sufentanil (bolus 0.25 µg/kg)
Study: 29128486
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose sufentanil (bolus 0.5 µg/kg)
Study: 25496243
Drug: Immediate implant
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate implant placement and immediate temporary restoration
Study: 25496243
Drug: Immediate implant
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate implant placement and early restoration
Study: 25496243
Drug: Early implant
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early implant placement and immediate temporary restoration
Study: 25496243
Drug: Early implant
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early implant placement and early restoration
Study: 12362542
Drug: Single daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single daily injection of low molecular weight heparin
Study: 12362542
Drug: Warfarin for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin for longer-term secondary prophylaxis